Hjem › Steatotisk leversykdom › Maryland
Kliniske studier for Steatotisk leversykdom i Maryland
8 studier for Steatotisk leversykdom søker deltakere på steder i Maryland.
Byer i Maryland
Offisiell studietekst (engelsk)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Baltimore
- 89bio Clinical Study Site, Glen Burnie
- 89bio Clinical Study Site, Greenbelt
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Baltimore
- 89bio Clinical Study Site, Glen Burnie
- 89bio Clinical Study Site, Greenbelt
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06318169A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Mercy Medical Center - Baltimore, Baltimore
- Capital Digestive Care - Chevy Chase, Chevy Chase
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Baltimore
- Akero Clinical Study Site, Bethesda
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 21. sep. 2026 · NCT06528314A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Mid-Atlantic GI Research, Greenbelt
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07288138Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- National Institutes of Health Clinical Center, Bethesda
RekruttererFase 2Frivillige helsepersonell ønskes velkommen
Alder 18 til 100 · Alle kjønn · Oppdatert 10. aug. 2026 · NCT03884075Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
- National Institutes of Health Clinical Center, Bethesda
RekruttererFase 1Frivillige helsepersonell ønskes velkommen
Alder 21 til 65 · Alle kjønn · Oppdatert 20. jul. 2026 · NCT04781322A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Baltimore
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 8. jul. 2026 · NCT06920043Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.